obesity
The combination noradrenergic/serotonergic agent       sibutramine is indicated for the management of obesity, particularly in the       presence of other cardiovascular risk factors.
The combination noradrenergic/serotonergic agent       sibutramine is indicated for the management of  @SUBJECT$ , particularly in the        @PREDICAT$  of other  @OBJECT$ .